Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 99 EP1309 | DOI: 10.1530/endoabs.99.EP1309

Ibn Sina University Hospital, Endocrinology and Metabolic Diseases, Rabat, Morocco


Introduction: Developing in the adrenal medulla’s chromaffin cells, pheochromocytoma (PC) is an infrequent tumor Illustrating the instance of a patient diagnosed with malignant adrenal pheochromocytoma (PCM) following the onset of paralyzing sciatic pain

Case: A 60-year-old patient managing hypertension with triple therapy and type 2 diabetes using metformin and insulin glargine. The patient sought emergency care due to recurrent and disabling sciatic pain progressing to paraplegia. Concurrent constitutional symptoms, significant weight loss, and anorexia prompted a lumbar spine MRI, revealing spinal cord compression with an L3 fracture, and a concurrent 88mm adrenal mass, as further confirmed by an abdominopelvic CT scan. Secretory biochemical analysis indicated a significant increase in plasma Normetanephrines, measuring 116 times the normal level, while Metanephrines remained within the normal range. An 18F-FDG PET scan performed for staging purposes confirmed the hypermetabolic adrenal mass and identified a vertebral tumor extension with comparable features to the adrenal tumor. Surgical intervention has been advised after medical preparation.

Discussion: A neuroendocrine tumor, pheochromocytoma, is an infrequent condition marked by excessive catecholamine secretion. Malignancy is noted in 10% of cases, determined by metastases in tissues lacking chromaffin cells. It has a hereditary component in 40% of cases and in order to provide the best care, a coordinated, multidisciplinary approach is imperative

Volume 99

26th European Congress of Endocrinology

Stockholm, Sweden
11 May 2024 - 14 May 2024

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.